Advertisement
 
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

AstraZeneca Q1 Profit Up 29%

April 29, 2010 6:16 am | News | Comments

Anglo-Swiss pharmaceutical company AstraZeneca PLC reported that first-quarter profit rose by 29 percent, but cautioned that comparisons will be tougher in the second half of the year when a key patent expires.

TOPICS:

Integrated Response Technology

April 29, 2010 6:11 am | Product Releases | Comments

endpoint Clinical announced that PULSE, a fully configurable platform that allows users to design and deploy clinical trial Integrated Response Technology (IRT) systems, saves 40 percent on the development time of clinical trials.

TOPICS:

TrialTrove Reaches Landmark 100k Trial

April 29, 2010 6:06 am | News | Comments

Citeline’s TrialTrove, a leading global pharmaceutical intelligence service, now tracks more than 100,000 clinical trials around the world, making it among the most comprehensive source of clinical trial information available.

TOPICS:
Advertisement

Cardiac Safety Software

April 29, 2010 5:57 am | Product Releases | Comments

ERT, a leading provider of centralized services to the biopharmaceutical, medical device and related industries, announced the launch of Centralized Cardiac Safety 2.0, a portfolio of new solutions that enable a significant new approach to cardiac safety in clinical trials.

TOPICS:

Trial Reporting

April 29, 2010 5:49 am | Product Releases | Comments

Almac Clinical Technologies announced the release of a new reporting solution for its IXRS integrated phone and web response technology, Almac Interactive Reporting.

TOPICS:

Access Array System

April 28, 2010 6:29 am | Product Releases | Comments

Fluidigm Corporation released a protocol for the Access Array System that enables sequencing of amplicon libraries using GS FLX Titanium Series reagents on the 454 GS FLX sequencing system.

TOPICS:

Sample Processor

April 28, 2010 6:24 am | Product Releases | Comments

Life Technologies Corporation debuted the life science industry’s first benchtop sample preparation system designed to increase productivity while eliminating manual and contamination-related challenges traditionally associated with protein and epigenetic protocols.

TOPICS:

Debiopharm Begins Enrollment for Debio 0932

April 28, 2010 6:20 am | News | Comments

Debiopharm Group announced that it has started patient enrolment in its Phase 1 clinical trial for the small molecule inhibitor of heat shock protein 90 (Hsp90), Debio 0932.

TOPICS:
Advertisement

Shire Receives Paragraph IV Notice for INTUNIV

April 28, 2010 6:16 am | News | Comments

Shire plc announces that it has received a Paragraph IV Notice Letter from Anchen Pharmaceuticals, Inc. advising of the filing of an abbreviated new drug application for a generic version of Shire’s INTUNIV.

TOPICS:

Lucentis Improves Vision in Diabetic Macular Edema

April 28, 2010 6:10 am | News | Comments

Researchers have shown that ranibizumab (Lucentis) eye injections, often in combination with laser treatment, result in better vision than laser treatment alone for diabetes-associated swelling of the retina.

TOPICS:

Researchers Find Possible Treatment for Bone Death

April 28, 2010 6:06 am | News | Comments

Researchers at Mount Sinai School of Medicine have found a potential new treatment for osteonecrosis, or the death of bone tissue, in people who are treated with steroids for several common medical conditions.

TOPICS:

Phase Forward Profits Down 53%

April 28, 2010 6:02 am | News | Comments

Phase Forward Inc., a provider of data management software for drug safety and clinical trials, said its first-quarter profit fell 53 percent as business costs and operating expenses outstripped modest revenue gains.

TOPICS:

Merck KGaA Profits Up Quarter Billion Dollars in Q1

April 28, 2010 5:58 am | News | Comments

The overall increase in profit came as revenues at the company, which also makes the cancer drug Erbitux and multiple sclerosis treatment Rebif, rose nearly 13 percent to nearly €2.1 billion in the January-March period compared with nearly €1.9 billion a year earlier.

TOPICS:

Dirty Bomb Test May Help Cancer Researchers

April 28, 2010 5:52 am | by Lauran Neergaard | News | Comments

With a few drops of blood, scientists are creating a way to tell who's absorbed dangerous radiation levels, part of the government's preparations against a terrorist attack - and research that just might point toward new cancer care, too.

TOPICS:

Novo Nordisk 1st Quarter Profits Rise 23%

April 28, 2010 5:47 am | News | Comments

Danish drug maker Novo Nordisk A/S said its first quarter profit soared 23 percent, helped by increased sales of its core insulin products.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading